Preferred Label : Mogamulizumab;
NCIt synonyms : Immunoglobulin G1, Anti-(CC Chemokine Receptor CCR4) (Human-Mouse Monoclonal KW-0761
Heavy Chain), Disulfide With Human-Mouse Monoclonal KW-0761 Kappa-Chain, Dimer; Mogamulizumab-kpkc;
NCIt definition : A humanized monoclonal antibody directed against C-C chemokine receptor 4 (CCR4) with
potential anti-inflammatory and antineoplastic activities. Mogamulizumab selectively
binds to and blocks the activity of CCR4, which may inhibit CCR4-mediated signal transduction
pathways and, so, chemokine-mediated cellular migration and proliferation of T cells,
and chemokine-mediated angiogenesis. In addition, this agent may induce antibody-dependent
cell-mediated cytotoxicity (ADCC) against CCR4-positive T cells. CCR4, a G-coupled-protein
receptor for C-C chemokines such MIP-1, RANTES, TARC and MCP-1, is expressed on the
surfaces of some types of T cells, endothelial cells, and some types of neurons. CCR4,
also known as CD194, may be overexpressed on adult T-cell lymphoma (ATL) and peripheral
T-cell lymphoma (PTCL) cells.;
UNII : YI437801BE;
CAS number : 1159266-37-1;
Drug name : Poteligeo;
Molecule name : KW-0761; KM8761; KW 0761;
Codes from synonyms : 338;
Origin ID : C62510;
UMLS CUI : C2987603;
Automatic exact mappings (from CISMeF team)
- Currated CISMeF NLP mapping
- See also inter- (CISMeF)
- Semantic type(s)
- UMLS correspondences (same concept)
- Validated automatic mappings to BTNT
- chemical_or_drug_affects_cell_type_or_tissue
- chemical_or_drug_has_mechanism_of_action
- chemical_or_drug_has_physiologic_effect
- concept_is_in_subset
- has_target
- is_component_of_chemotherapy_regimen
